Tag Archives: RESOLVE-1

Onswik FDA Approval; Lilly Medicare GLP-1 Bridge Program Market Share; BI + WHO Global Metabolic Health Collaboration; Roche + Atavistik Partner for Allosteric Drug Discovery; Aqua Medical T2DM Endoscopic Procedure; Biolinq Shine OTC FDA Clearance; Rezera RESOLVE-1 AHA Presentation

A series of cardiometabolic-related news items has been observed from Lilly, BI/WHO, Roche/Atavistik Bio, Aqua Medical, Biolinq, and Rezera. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Ascletis FIH Oral Amylin Study; Moonwalk $70M Series B; New Lilly Obesity Asset; Kura Oncology Spins Out Diabetes Business; MannKind Partners for Inhaled GLP-1RA; NodThera Name Change and Topline Ph2 NLRP3i Data

A series of cardiometabolic-related news items has been observed from Ascletis Pharma, Moonwalk Biosciences, Lilly, Kura Oncology/Caspian Therapeutics, MannKind, and NodThera. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Welldoc Supports Launch of New Lilly Health App; NodThera Initiates Ph2 Study of NT-0796; Virta Claims Cost Savings for Obesity Programs

Three cardiometabolic-related news items have been observed: Welldoc announced it will power Lilly’s new app for obesity (view press release); NodThera initiated its Ph2 RESOLVE-1 study for NT-0796 in obesity (view press release); and Virta Health announced cost savings for health plans and employers utilizing its cardiometabolic programs (view press release). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here